BlackRock
SABS icon

BlackRock’s SAB Biotherapeutics SABS Stock Holding History

BlackRock’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12M Buy
3,066,016
+2,764,690
+918% +$10.3M ﹤0.01% 3582
2026
Q1 		$1.15M Buy
301,326
+284,087
+1,648% +$1.13M ﹤0.01% 4287
2025
Q4 		$64.5K Buy
17,239
+10,900
+172% +$35.9K ﹤0.01% 4996
2025
Q3 		$12.7K Sell
6,339
-667
-10% -$1.51K ﹤0.01% 5198
2025
Q2 		$12.3K Sell
7,006
-15,295
-69% -$25.3K ﹤0.01% 5199
2025
Q1 		$30.3K Sell
22,301
-303
-1% -$695 ﹤0.01% 5020
2024
Q4 		$85.8K Buy
22,604
+439
+2% +$1.44K ﹤0.01% 4821
2024
Q3 		$59.8K Buy
22,165
+8,413
+61% +$23.3K ﹤0.01% 4772
2024
Q2 		$42.6K Buy
13,752
+7,413
+117% +$27.2K ﹤0.01% 4897
2024
Q1 		$28.8K Buy
6,339
+1,075
+20% +$5.92K ﹤0.01% 4980
2023
Q4 		$36.2K Hold
5,264
– – ﹤0.01% 5015
2023
Q3 		$33.2K Hold
5,264
– – ﹤0.01% 5075
2023
Q2 		$43.7K Sell
5,264
-5,737
-52% -$47K ﹤0.01% 5085
2023
Q1 		$48.4K Buy
11,001
+186
+2% +$1.18K ﹤0.01% 5125
2022
Q4 		$63.8K Sell
10,815
-1,757
-14% -$16.1K ﹤0.01% 5163
2022
Q3 		$88K Sell
12,572
-173
-1% -$1.72K ﹤0.01% 5216
2022
Q2 		$185K Buy
12,745
+5,493
+76% +$115K ﹤0.01% 5057
2022
Q1 		$273K Buy
7,252
+91
+1% +$4.2K ﹤0.01% 5036
2021
Q4 		$559K Buy
+7,161
New +$672K ﹤0.01% 4839

Other funds holding SABS

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BlackRock's SABS Position: Q2 2026 in Review

BlackRock increased its SAB Biotherapeutics (SABS) stake by 918% in Q2 2026, buying an estimated $10.3M and bringing the position to 3,066,016 shares worth $12M. The position accounts for ﹤0.01% of the portfolio, ranked #3582.

BlackRock first reported a position in SABS in Q4 2021 and has held it in 19 quarters since. 46 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • BlackRock held 3,066,016 shares of SAB Biotherapeutics worth $12M as of Q2 2026.
  • BlackRock bought 2,764,690 SAB Biotherapeutics shares in Q2 2026, an estimated $10.3M.
  • SAB Biotherapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3582 holding.
  • BlackRock first reported a position in SAB Biotherapeutics in Q4 2021 and has held it in 19 quarters since.
  • 46 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.